Innovative antisense therapy blocking production of TGF-β2 shows promise in reducing retinal fibrosis and improving outcomes ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the ...

Just like many of The Ordinary’s bestselling products, the growth factor 15 percent solution comes in the brand’s signature ...

Keros' cash and cash equivalents as of March 31, 2025 was $720.5 million compared to $559.9 million as of December 31, 2024.

Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA 1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 ...

Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...

Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo Broader Therapeutic Potential: Positive Phase 2 results in both uterine ...

- Cash Position: Cash and cash equivalents were $101.6 million as of March 31, 2025, compared to $34.6 million as of December 31, 2024, bolstered by $76.4 million in gross proceeds from the first ...

Calcium signaling plays a fundamental role in cardiac development and function, orchestrating a wide array of cellular processes that are essential for ...